Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate. Per the terms of the agreement, both companies will develop and commercialize petrelintide,
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.
Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn
Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
STAT2d
Lilly CEO got a big payday (and an Olympics treat)
Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...
pharmaphorum10mon
Roche trumpets potential ‘best-in-class’ obesity drug
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...